Cryotherapy technology company CSA Medical reported on Wednesdaythat its RejuvenAir System has been designated as a Breakthrough Device by the US Food and Drug Administration (FDA).
Additionally, the company has received unconditional IDE (Investigational Device Exemption) approval to initiate a pivotal clinical study to treat patients with moderate to severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB).
The RejuvenAir System delivers a Metered Cryospray of liquid nitrogen at -196 degrees C to targeted areas within the lungs. It is anticipated that the rapid freezing of the epithelial layer of the airway walls will destroy the mucus-producing goblet cells while preserving the extracellular matrix, thereby enabling the regrowth of healthy cells.
COPD, which includes CB, is a long-term, progressive lung disease that over time makes it hard to breathe and is the third leading cause of disease-related deaths in the United States.
The company plans to launch the pivotal, prospective, multi-centre, blinded randomized (2:1) sham controlled trial using the RejuvenAir System across 30 sites in the US, Europe and Canada with up to 330 subjects with moderate to severe COPD with CB.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project